| Popis: |
Mitochondrial disorders are a group of neurometabolic and neurodegenerative diseases caused by impairment of the mitochondrial respiratory chain. There is no clear evidence supporting any pharmacological interventions for the majority of mitochondrial disorders, except Leber hereditary optic neuropathy, coenzyme Q10 deficiencies, and mitochondrial neurogastrointestinal encephalomyopathy. Furthermore, some drugs may have detrimental effects on mitochondrial function. Drugs known to be “mitochondrion-toxic” should be avoided whenever possible in these patients. In this chapter, we discuss the new therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders, with special attention to mitochondrial diseases. We will also briefly discuss their potential role in more “conventional” neurodegenerative disorders. |
